NF-κB nuclear localization and its prognostic significance in prostate cancer

BJU International

Volumn 91, Issue 4, 2003, Pages 417-420

  Lessard, L ^a   Mes Masson, A M ^a   Lamarre, L ^a   Wall, L ^a   Lattouf, J B ^a   Saad, F ^a,b  

^a NOTRE DAME HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Gleason grade; Immunohistochemistry; NF B; Prognostic marker; Prostatic neoplasm

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; SYNAPTOTAGMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN LOCALIZATION; SCORING SYSTEM; STAINING; VALIDATION PROCESS;

AGED; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037351342     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04104.x     Document Type: Article

References (29)

1. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pothol 1994; 18: 796-803
2. Grossfeld GD, Chang JJ, Broering JM et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001; 165: 851-6
3. Gilmore TD. The ReI/NF-kappaB signal transduction pathway: introduction. Oncogene 1999; 18: 6842-4
4. Karin M, Ben-Neriah Y. Phosphorylation meets ubíquitinatíon: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63
5. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 (Suppl): S81-96
6. Barkett M, Gilmore TD. Control of apoptosis by ReI/NF-kappaB transcription factors. Oncogene 1999; 18: 6910-24
7. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-6
8. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2: 301-10
9. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B ReIA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-27.7
10. Sovak MA, Bellas RE, Kim DW et al. Aberrant nuclear factor-kappaB/ReI expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952-60
11. Kim DW, Sovak MA, Zanieski G et al. Activation of NF-kappaB/ReI occurs early during neoplastic transformation of mammary cells. Corcinogenesis 2000; 21: 8719
12. Sumitomo M, Tachibana M, Nakashima J et al. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999; 161: 674-9
13. Herrmann JL, Beham AW, Sarkiss M et al. BCL-2 suppresses apoptosis resulting from disruption of the NF-κB pathway. Exp Cell Res 1997; 237: 101-9
14. Chen CD, Sawyers CS. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002; 22: 2862-70
15. Gasparian AV, Yao YJ, Kowalczyk D et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115: 141-51
16. Palayoor ST, Yournell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-94
17. Suh J, Payvandi F, Edelstein LC et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52: 183-200
18. Gleason DF. Histologic grading of prostate cancer: a perspective. Human Path 1992; 23: 273-9
19. Wang CY, Mayo MW, Baldwin AS Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-7
20. Wang CY, Mayo MW, Korneluk RG et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3
21. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdascy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2000; 18: 471-9
22. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-97
23. Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001; 276: 27740-4
24. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14: 2410-34
25. Vanden Berghe W, De Bossener K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transciptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-8
26. Chung TD, Yu JJ, Spiotto M, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38: 199-207
27. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-6
28. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-65
29. Suda T, Takahashi N, Udagawa N, Jimi E, Gillepsie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrinol Rev 1999; 20: 347-57